On Monday, biotech
company Moderna announced its incomplete findings from a Phase 1 clinical trial of the vaccine
candidate, called mRNA-1273.
According to the company, three people who took the highest dose of the vaccine
experienced a grade 3 adverse event after the second dose, while one person in the 100-milligram group experienced grade 3 redness around the injection site.
In the 25-milligram group, two weeks after the second dose, all of the volunteers appeared to show levels of binding antibodies
similar to those seen in plasma
donated from recovered covid-19 patients.
While this is the first research released from a human trial of a potential covid-19 vaccine, Moderna’s data has yet to be independently verified and isn’t complete.
According to the company, preparations are now underway for larger, Phase 2 trials of the vaccine, which will involve people taking a 50- or 100-milligram dose.